Bloomberg Law
Drug, Device Manufacturers to Face Hill Scrutiny in 2019
January 8, 2019
Combating high drug and device prices is a bipartisan goal in Congress, and House Democrats in control of key oversight committees have made clear their plans to pursue investigations putting pharma CEOs under scrutiny. Manufacturers need to prep now to explain policies and prepare for public relations issues.
Contacts
Capabilities
Suggested News & Insights
Medical Products Market Access: Favorable Advisory Opinion Reaffirms Discounting FlexibilitiesJanuary 21, 2026FY 2025 FCA Settlements and Judgments Statistics Show Highest Recoveries EverJanuary 20, 2026Korea Night @ JPM 2026Wednesday, January 14, 2026Recharge & Recaffeinate with Sidley @ JPMMonday, January 12, 2026 – Tuesday, January 13, 2026Biotech Dealmaking – Regulatory Considerations for the Next Wave of Development-Stage Transactions – Program and Lunch @ JPM 2026Monday, January 12, 2026Sidley Represents Smith+Nephew in Integrity Orthopaedics Acquisition Valued Up to US$450 MillionJanuary 12, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory